These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 19900026)

  • 1. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.
    Bays HE
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1429-45. PubMed ID: 19900026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
    Bays H
    Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.
    Smith SR; Prosser WA; Donahue DJ; Morgan ME; Anderson CM; Shanahan WR;
    Obesity (Silver Spring); 2009 Mar; 17(3):494-503. PubMed ID: 19057523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?
    Bays H; Blonde L; Rosenson R
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):871-95. PubMed ID: 17173503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development.
    Bays HE
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):265-77. PubMed ID: 21438803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of lorcaserin in the management of obesity.
    Hess R; Cross LB
    Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter, placebo-controlled trial of lorcaserin for weight management.
    Smith SR; Weissman NJ; Anderson CM; Sanchez M; Chuang E; Stubbe S; Bays H; Shanahan WR;
    N Engl J Med; 2010 Jul; 363(3):245-56. PubMed ID: 20647200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.
    Smith BM; Smith JM; Tsai JH; Schultz JA; Gilson CA; Estrada SA; Chen RR; Park DM; Prieto EB; Gallardo CS; Sengupta D; Dosa PI; Covel JA; Ren A; Webb RR; Beeley NR; Martin M; Morgan M; Espitia S; Saldana HR; Bjenning C; Whelan KT; Grottick AJ; Menzaghi F; Thomsen WJ
    J Med Chem; 2008 Jan; 51(2):305-13. PubMed ID: 18095642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel?
    Miller KJ; Wacker DA
    Future Med Chem; 2010 Dec; 2(12):1761-75. PubMed ID: 21428799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
    Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lorcaserin: an investigational serotonin 2C agonist for weight loss.
    Hurren KM; Berlie HD
    Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials.
    Weissman NJ; Sanchez M; Koch GG; Smith SR; Shanahan WR; Anderson CM
    Circ Cardiovasc Imaging; 2013 Jul; 6(4):560-7. PubMed ID: 23661689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.
    Nguyen CT; Zhou S; Shanahan W; Fain R
    Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adiposopathy is "sick fat" a cardiovascular disease?
    Bays HE
    J Am Coll Cardiol; 2011 Jun; 57(25):2461-73. PubMed ID: 21679848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability review of lorcaserin in clinical trials.
    Greenway FL; Shanahan W; Fain R; Ma T; Rubino D
    Clin Obes; 2016 Oct; 6(5):285-95. PubMed ID: 27627785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases.
    Wacker DA; Miller KJ
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):438-45. PubMed ID: 18600561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.
    Ahmad S; Ngu K; Miller KJ; Wu G; Hung CP; Malmstrom S; Zhang G; O'Tanyi E; Keim WJ; Cullen MJ; Rohrbach KW; Thomas M; Ung T; Qu Q; Gan J; Narayanan R; Pelleymounter MA; Robl JA
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1128-33. PubMed ID: 20022752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists.
    Higgins GA; Sellers EM; Fletcher PJ
    Trends Pharmacol Sci; 2013 Oct; 34(10):560-70. PubMed ID: 24041919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.
    Nigro SC; Luon D; Baker WL
    Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2 new drugs for weight loss.
    Med Lett Drugs Ther; 2012 Sep; 54(1398):69-71. PubMed ID: 22992487
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.